Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity
Biogen announced positive Phase 2 results from the AMETHYST study for litifilimab, an investigational monoclonal antibody targeting BDCA2, demonstrating statistically significant improvement in skin disease activity in patients with cutaneous lupus erythematosus (CLE). These consistent positive results, along with a favorable safety profile and FDA…